Cancer Immunotherapy Market - Forecast(2024 - 2030)

Report Code: HCR 0197 Report Format: PDF + Excel

Cancer Immunotherapy Market Overview

The Cancer Immunotherapy Market Size is estimated to reach $152.6 billion by 2028 and it is poised to grow at a CAGR of 14.7% over the forecast period of 2023-2028. Cancer immunotherapy is a rapidly growing form of cancer treatment, which is designed to use the body’s own immune system to attack and prevent cancer cells from growing and forming. Immunotherapy carries immense market potential with several pharmaceutical industry companies actively working towards getting FDA approval. Some of the common forms of cancer immunotherapy types are monoclonal antibodies, immunomodulators, cancer vaccines, oncolytic viral therapies and cell therapy. A significant increase in the incidence of various cancer types rightly aids in the growth of the market, as new players are trying to fund various clinical research for advanced treatment. According to World Health Organisation (WHO), Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. A growing clinical base substantiated by significant investments from private and public players forms a moderate to high industry outlook for the Cancer Immunotherapy Market.

Cancer Immunotherapy Market Report Coverage

The report: “Cancer Immunotherapy Market Forecast (2023-2028)" by IndustryARC, covers an in-depth analysis of the following segments in the Cancer Immunotherapy Market.

By Type: Immune Checkpoint Inhibitors, T-cell Transfer Therapy, Monoclonal Antibodies, Treatment Vaccines and Immune System Modulators.
By Cancer: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer and Others.
By Route of Administration: Intravenous, Oral, Topical and Intravesical.
By Geography: North America (the U.S., Canada and Mexico), Europe (Germany, Uthe UK, France, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan India, South Korea, Australia and New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).

Key Takeaways

  • Geographically, North America held a dominant market share in 2022. It is due to a plethora of market players providing extensive research and development services along with a nuanced and favorable environment for pharmaceutical finances. However, Asia-Pacific is expected to offer lucrative growth opportunities over the forecast period of 2023-2028.
  • A growing population base of cancer across the region supplemented by ailing immunotherapies as a mode to tackle cancer aids market growth. However, extensive usage of other cancer treatments along with the high cost associated with immunotherapies impede the market growth.
  • A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Cancer Immunotherapy Market Report.

Cancer Immunotherapy Market- Market Share (%) by region, 2022.

Cancer Immunotherapy Market

For More Details on This Report - Request for Sample

Cancer Immunotherapy Market Segment Analysis - by Type

Cancer Immunotherapy Market based on type can be further segmented into Immune Checkpoint Inhibitors, T-cell Transfer Therapy, Monoclonal Antibodies, Treatment Vaccines and Immune System Modulators. Monoclonal Antibodies held a dominant market share in 2022 and are estimated to be the fastest-growing type, with a CAGR of 15.9% over the forecast period of 2023-2028. Monoclonal antibodies flag cancer cells, triggers cell-membrane destruction, block cell growth, prevents blood vessel growth and various other function in resolving cancer. This form of treatment methodology is highly prescribed by doctors across the countries due to higher specificity and better cost control along with a safety profile. Moreover, this segment provides a targeted approach that rightly aids market growth. Moreover, as per a recent statement of Bristol Myers Squibb, around a 5% increase in revenues from Opdivo and Yervooy was reported in Q1 2022 against Q1 2021.

Cancer Immunotherapy Market Segment Analysis - by Cancer

The Cancer Immunotherapy Market based on cancer type can be further segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer and Others. Lung Cancer held a dominant market share in 2022. It is owing to the high prevalence of this cancer type and the availability and effectiveness of immunotherapy to aid. As per the American Cancer Society, nearly 236,000 new lung cancer cases would be diagnosed in the U.S. in 2022 with high prevalence in older people than younger generations. However, Breast Cancer is estimated to be the fastest-growing cancer type, with a CAGR of 15.7% over the forecast period of 2023-2028. As per BreastCancer.Org, nearly 1 in 8 women in the U.S. would develop cancer each year. Critically, the rampant utilization of drugs such as dostarlimab and pembrolizumab as immune checkpoint inhibitors would aid market growth.

Cancer Immunotherapy Market Segment Analysis - by Geography

North America held a dominant market share of nearly 43% in 2022. This is owing to the presence of a large number of companies. Also, various strategic initiatives are undertaken by both private and public players to eradicate cancer. Active drug regularization from leading authorities allows for the launch in commercial settings which rapidly aids market growth. As per Cancer Statistics Canada 2021, nearly 229,200 cancer cases were diagnosed in the country, with an incidence of 2 in 5 Canadians developing cancer over a lifetime. However, Asia-Pacific is expected to offer lucrative growth opportunities over the forecast period of 2023-2028 owing to significant development in regions like Korea, Japan and India which would aid the market participation.

Cancer Immunotherapy Market Drivers

Substantial Case Growth in a Variety of Cancer Types:

The proliferation of cancer can start in almost any organ of the body and turn into a malignant form of the disease in no time. As per WHO, cancer is the second leading cause of death globally, with nearly one in six deaths in 2019 alone. Some of the common forms of cancer in men recorded are lung, prostate, colorectal, stomach and liver cancer, whilst breast, colorectal, lung and cervical cancer were the most recorded in women. As per WHO 2020, nearly 2.26 million cases of breast cancer were diagnosed, amongst various other forms of cancer. The usage of immunotherapy rightly aids in market growth.

Substantiated Research and Development Activities Pertinent to Immunotherapy:

A high focus on the development of immunotherapy as a form of treatment for cancer is seen in leading countries, especially, the HDE (Highly Developed Economies). As per Cancer Research Institute UK, nearly $400 million is invested by the organization each year for the prevention, diagnosis and treatment of cancer. Similarly, in 2022, nearly $13 million was granted to Stanford Scientists by U.S. National Cancer Institute and Cancer Research UK for Cancer Treatment. Furthermore, rampant clinical research trials using e-tools have successfully aided in the deployment of immunotherapy as a treatment form. Lastly, around 13 antibody therapeutical drugs were granted approval from 2019-2021 (January) within the EU and the U.S.

Cancer Immunotherapy Market Challenges

High Prevalence of Alternate Treatment Methodologies for Cancer along with Significant Price Challenges:

As per Cancer.Gov, immunotherapy drugs have received wide recognition across the treatment class. However, it is not as widely used as surgery, chemotherapy or radiation therapy. As per Cancer Research UK, nearly 45% of treatment cases for cancer in the United Kingdom opt for surgery; 28% for chemotherapy and nearly 27% for radiotherapy. Furthermore, the cost of utilizing immunotherapy as a treatment method is highly expensive. For example, CAR-T Therapy costs above $475,000 per patient (Kymirah). Similarly, monoclonal antibodies for Nivolumab are $6580 per infusion. These factors hamper the market growth.

Key Market Players

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Cancer Immunotherapy Industry. The top 10 companies in the Cancer Immunotherapy Market are:

  1. Pfizer Inc
  2. Astra Zeneca
  3. Merck and Co
  4. F-Hoffman-La Roche
  5. Bristol Myers Squibb Company
  6. Novartis AG
  7.  Lily
  8. Johnson and Johnson
  9.  Immunocore
  10. BioNTech

Recent Developments

  • In October 2022, Researchers from the University of Rhode Island and Yale University demonstrated the efficacy of a promising new approach to deliver immunotherapy agents to fight cancer. The approach is known as the Stimulator of Interferon Gene Agonist to an acid-seeking molecule called pH-low insertion peptide.
  • In October 2022, the FDA approved a new immunotherapy drug for advanced liver cancer. The drug is known as IMJUDO. It is for use in the combination immunotherapy regimen for adults with HCC or Hepatocellular Carcinoma Cancer.
  • In February 2022, BioNTech and MEDIGENE announced a global collaboration to advance T-cell Receptor Immunotherapies against Cancer. As per the agreement, MEDIGENE would receive EUR 26 million upfront from BioNTech under research funding.

Relevant Titles

Monoclonal Antibodies Market - Industry Analysis, Market Size, Market Share, Trends Analysis, Application Analysis and Forecast Analysis.

Report Code: HCR 0320

Cancer Diagnostics Market - Industry Analysis, Market Size, Market Share, Trends Analysis, Application Analysis and Forecast Analysis.

Report Code: HCR 0195

Regenerative Medicine Market - Industry Analysis, Market Size, Market Share, Trends Analysis, Application Analysis and Forecast Analysis.

Report Code: HCR 0366

For more Lifesciences and Healthcare Market reports, please click here

1. Cancer Immunotherapy Market - Overview
    1.1 Definitions and Scope
2. Cancer Immunotherapy Market - Executive Summary
3. Cancer Immunotherapy Market - Comparative Analysis
    3.1 Company Benchmarking - Key Companies
    3.2 Global Financial Analysis - Key Companies
    3.3 Market Share Analysis - Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Cancer Immunotherapy Market - Start-up Companies Scenario Premium
    4.1 Key Start-up Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Cancer Immunotherapy Market – Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Cancer Immunotherapy Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porter's Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Cancer Immunotherapy Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Cancer Immunotherapy Market – by Type
    8.1 Immune Checkpoint Inhibitor
    8.2 T-cell Transfer Therapy
    8.3 Monoclonal Antibodies
    8.4 Treatment Vaccines
    8.5 Immune System Modulators
9. Cancer Immunotherapy Market – by Cancer
    9.1 Lung Cancer
    9.2 Breast Cancer
    9.3 Colorectal Cancer
    9.4 Melanoma
    9.5 Prostate Cancer
    9.6 Head and Neck Cancer
    9.7 Ovarian Cancer
    9.8 Pancreatic Cancer
    9.9 Others
10. Cancer Immunotherapy Market - by Route of Administration
    10.1 Intravenous
    10.2 Oral
    10.3 Topical
    10.4 Intravesical
11. Cancer Immunotherapy Market - by Geography
    11.1 North America
        11.1.1 The US
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 The UK
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 The Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 The Rest of Asia-Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Chile
        11.4.4 Colombia
        11.4.5 The Rest of South America
    11.5 The Rest of the World
        11.5.1 The Middle East
        11.5.2 Africa
12. Cancer Immunotherapy Market - Entropy
13. Cancer Immunotherapy Market – Industry/Segment Competition Landscape Premium 
    13.1 Market Share Analysis
        13.1.1 Market Share by Region – Key companies
        13.1.2 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Cancer Immunotherapy Market – Key Company List by Country Premium Premium
15. Cancer Immunotherapy Market - Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
* "Financials would be provided to private companies on best-efforts basis." 
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.
List of Tables

Table 1: Cancer Immunotherapy Market Overview 2021-2026
Table 2: Cancer Immunotherapy Market Leader Analysis 2018-2019 (US$)
Table 3: Cancer Immunotherapy Market Product Analysis 2018-2019 (US$)
Table 4: Cancer Immunotherapy Market End User Analysis 2018-2019 (US$)
Table 5: Cancer Immunotherapy Market Patent Analysis 2013-2018* (US$)
Table 6: Cancer Immunotherapy Market Financial Analysis 2018-2019 (US$)
Table 7: Cancer Immunotherapy Market Driver Analysis 2018-2019 (US$)
Table 8: Cancer Immunotherapy Market Challenges Analysis 2018-2019 (US$)
Table 9: Cancer Immunotherapy Market Constraint Analysis 2018-2019 (US$)
Table 10: Cancer Immunotherapy Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Cancer Immunotherapy Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Cancer Immunotherapy Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Cancer Immunotherapy Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Cancer Immunotherapy Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Cancer Immunotherapy Market Value Chain Analysis 2018-2019 (US$)
Table 16: Cancer Immunotherapy Market Pricing Analysis 2021-2026 (US$)
Table 17: Cancer Immunotherapy Market Opportunities Analysis 2021-2026 (US$)
Table 18: Cancer Immunotherapy Market Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Cancer Immunotherapy Market Supplier Analysis 2018-2019 (US$)
Table 20: Cancer Immunotherapy Market Distributor Analysis 2018-2019 (US$)
Table 21: Cancer Immunotherapy Market Trend Analysis 2018-2019 (US$)
Table 22: Cancer Immunotherapy Market Size 2018 (US$)
Table 23: Cancer Immunotherapy Market Forecast Analysis 2021-2026 (US$)
Table 24: Cancer Immunotherapy Market Sales Forecast Analysis 2021-2026 (Units)
Table 25: Cancer Immunotherapy Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 26: Cancer Immunotherapy Market By Type, Revenue & Volume,By Cancer monoclonal antibodies, 2021-2026 ($)
Table 27: Cancer Immunotherapy Market By Type, Revenue & Volume,By Naked monoclonal antibodies, 2021-2026 ($)
Table 28: Cancer Immunotherapy Market By Type, Revenue & Volume,By Immune checkpoint inhibitors, 2021-2026 ($)
Table 29: Cancer Immunotherapy Market By Type, Revenue & Volume,By Cancer vaccines, 2021-2026 ($)
Table 30: Cancer Immunotherapy Market By Type, Revenue & Volume,By Non-specific immunotherapies, 2021-2026 ($)
Table 31: North America Cancer Immunotherapy Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 32: South america Cancer Immunotherapy Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 33: Europe Cancer Immunotherapy Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 34: APAC Cancer Immunotherapy Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 35: Middle East & Africa Cancer Immunotherapy Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 36: Russia Cancer Immunotherapy Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 37: Israel Cancer Immunotherapy Market, Revenue & Volume,By Type, 2021-2026 ($)
Table 38: Top Companies 2018 (US$)Cancer Immunotherapy Market, Revenue & Volume
Table 39: Product Launch 2018-2019Cancer Immunotherapy Market, Revenue & Volume
Table 40: Mergers & Acquistions 2018-2019Cancer Immunotherapy Market, Revenue & Volume


List of Figures
Figure 1: Overview of Cancer Immunotherapy Market 2021-2026
Figure 2: Market Share Analysis for Cancer Immunotherapy Market 2018 (US$)
Figure 3: Product Comparison in Cancer Immunotherapy Market 2018-2019 (US$)
Figure 4: End User Profile for Cancer Immunotherapy Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Cancer Immunotherapy Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Cancer Immunotherapy Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Cancer Immunotherapy Market 2018-2019
Figure 8: Ecosystem Analysis in Cancer Immunotherapy Market 2018
Figure 9: Average Selling Price in Cancer Immunotherapy Market 2021-2026
Figure 10: Top Opportunites in Cancer Immunotherapy Market 2018-2019
Figure 11: Market Life Cycle Analysis in Cancer Immunotherapy Market
Figure 12: GlobalBy TypeCancer Immunotherapy Market Revenue, 2021-2026 ($)
Figure 13: Global Cancer Immunotherapy Market - By Geography
Figure 14: Global Cancer Immunotherapy Market Value & Volume, By Geography, 2021-2026 ($) 
Figure 15: Global Cancer Immunotherapy Market CAGR, By Geography, 2021-2026 (%)
Figure 16: North America Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 17: US Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 18: US GDP and Population, 2018-2019 ($)
Figure 19: US GDP – Composition of 2018, By Sector of Origin
Figure 20: US Export and Import Value & Volume, 2018-2019 ($)
Figure 21: Canada Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 22: Canada GDP and Population, 2018-2019 ($)
Figure 23: Canada GDP – Composition of 2018, By Sector of Origin
Figure 24: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 25: Mexico Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 26: Mexico GDP and Population, 2018-2019 ($)
Figure 27: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 28: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 29: South America Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 30: Brazil Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 31: Brazil GDP and Population, 2018-2019 ($)
Figure 32: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 33: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 34: Venezuela Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 35: Venezuela GDP and Population, 2018-2019 ($)
Figure 36: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 37: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 38: Argentina Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 39: Argentina GDP and Population, 2018-2019 ($)
Figure 40: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 41: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 42: Ecuador Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 43: Ecuador GDP and Population, 2018-2019 ($)
Figure 44: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 45: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 46: Peru Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 47: Peru GDP and Population, 2018-2019 ($)
Figure 48: Peru GDP – Composition of 2018, By Sector of Origin
Figure 49: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 50: Colombia Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 51: Colombia GDP and Population, 2018-2019 ($)
Figure 52: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 53: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 54: Costa Rica Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 55: Costa Rica GDP and Population, 2018-2019 ($)
Figure 56: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 57: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 58: Europe Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 59: U.K Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 60: U.K GDP and Population, 2018-2019 ($)
Figure 61: U.K GDP – Composition of 2018, By Sector of Origin
Figure 62: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 63: Germany Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 64: Germany GDP and Population, 2018-2019 ($)
Figure 65: Germany GDP – Composition of 2018, By Sector of Origin
Figure 66: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 67: Italy Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 68: Italy GDP and Population, 2018-2019 ($)
Figure 69: Italy GDP – Composition of 2018, By Sector of Origin
Figure 70: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 71: France Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 72: France GDP and Population, 2018-2019 ($)
Figure 73: France GDP – Composition of 2018, By Sector of Origin
Figure 74: France Export and Import Value & Volume, 2018-2019 ($)
Figure 75: Netherlands Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 76: Netherlands GDP and Population, 2018-2019 ($)
Figure 77: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 78: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 79: Belgium Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 80: Belgium GDP and Population, 2018-2019 ($)
Figure 81: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 82: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 83: Spain Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 84: Spain GDP and Population, 2018-2019 ($)
Figure 85: Spain GDP – Composition of 2018, By Sector of Origin
Figure 86: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 87: Denmark Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 88: Denmark GDP and Population, 2018-2019 ($)
Figure 89: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 90: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 91: APAC Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 92: China Cancer Immunotherapy Market Value & Volume, 2021-2026
Figure 93: China GDP and Population, 2018-2019 ($)
Figure 94: China GDP – Composition of 2018, By Sector of Origin
Figure 95: China Export and Import Value & Volume, 2018-2019 ($)Cancer Immunotherapy Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 96: Australia Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 97: Australia GDP and Population, 2018-2019 ($)
Figure 98: Australia GDP – Composition of 2018, By Sector of Origin
Figure 99: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 100: South Korea Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 101: South Korea GDP and Population, 2018-2019 ($)
Figure 102: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 103: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 104: India Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 105: India GDP and Population, 2018-2019 ($)
Figure 106: India GDP – Composition of 2018, By Sector of Origin
Figure 107: India Export and Import Value & Volume, 2018-2019 ($)
Figure 108: Taiwan Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 109: Taiwan GDP and Population, 2018-2019 ($)
Figure 110: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 111: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 112: Malaysia Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 113: Malaysia GDP and Population, 2018-2019 ($)
Figure 114: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 115: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 116: Hong Kong Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 117: Hong Kong GDP and Population, 2018-2019 ($)
Figure 118: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 119: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 120: Middle East & Africa Cancer Immunotherapy Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 121: Russia Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 122: Russia GDP and Population, 2018-2019 ($)
Figure 123: Russia GDP – Composition of 2018, By Sector of Origin
Figure 124: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 125: Israel Cancer Immunotherapy Market Value & Volume, 2021-2026 ($)
Figure 126: Israel GDP and Population, 2018-2019 ($)
Figure 127: Israel GDP – Composition of 2018, By Sector of Origin
Figure 128: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 129: Entropy Share, By Strategies, 2018-2019* (%)Cancer Immunotherapy Market 
Figure 130: Developments, 2018-2019*Cancer Immunotherapy Market 
Figure 131: Company 1 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 132: Company 1 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 133: Company 1 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 134: Company 2 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 135: Company 2 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 136: Company 2 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 137: Company 3Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 138: Company 3Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 139: Company 3Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 140: Company 4 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 141: Company 4 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 142: Company 4 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 143: Company 5 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 144: Company 5 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 145: Company 5 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 146: Company 6 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 147: Company 6 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 148: Company 6 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 149: Company 7 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 150: Company 7 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 151: Company 7 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 152: Company 8 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 153: Company 8 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 154: Company 8 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 155: Company 9 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 156: Company 9 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 157: Company 9 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 158: Company 10 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 159: Company 10 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 160: Company 10 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 161: Company 11 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 162: Company 11 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 163: Company 11 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 164: Company 12 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 165: Company 12 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 166: Company 12 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 167: Company 13Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 168: Company 13Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 169: Company 13Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 170: Company 14 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 171: Company 14 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 172: Company 14 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)
Figure 173: Company 15 Cancer Immunotherapy Market Net Revenue, By Years, 2018-2019* ($)
Figure 174: Company 15 Cancer Immunotherapy Market Net Revenue Share, By Business segments, 2018 (%)
Figure 175: Company 15 Cancer Immunotherapy Market Net Sales Share, By Geography, 2018 (%)